Pfizer
The primary purpose of this study is to understand how the body processes the study medicine, called prifetrastat, in people with renal impairment compared to healthy people with normal kidney function. Renal impairment means that a person has worse kidney function than normal. The study will also look at the safety and tolerability of prifetrastat in people with renal impairment compared to healthy people with normal kidney function. This study is seeking participants who: * Have moderate or severe renal impairment or * Healthy people with normal kidney function All participants in this study will receive a single dose of prifetrastat. The study medicine will be given by mouth at the study clinic. We will compare experiences of people with renal impairment and healthy people with normal kidney function. Participants will take part in this study for about 2 months. During this time, they will stay at the study clinic for 8 to 16 days.
Inclusion Criteria * Female of nonchildbearing potential or males, 18 to 90 years of age at screening. * Body mass index (BMI) of 16-40 kg/m2; and a total body weight \>50 kg (110 lb). * Stable renal function that matches the classification of either moderate renal impairment, severe renal impairment, or normal renal function. Exclusion Criteria * Any condition possibly affecting drug absorption * Acute renal disease * Renal allograft recipient * Renal transplant recipient * Urinary incontinence without catheterization * Current use of any prohibited concomitant medication(s)
Prifetrastat administered by mouth as a single dose.